Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)
13. März 2024 07:55 ET
|
Catalyst Pharmaceuticals, Inc.
AGAMREE® (vamorolone) a Novel Alternative Corticosteroid with Demonstrated Properties in Maintaining Efficacy and a Well-Tolerated Side Effect Profile Available in the U.S. by Prescription for...
Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
28. Februar 2024 18:03 ET
|
Catalyst Pharmaceuticals, Inc.
Achieved Record 2023 Total Revenues of $398.2 Million, an 85.9% Increase Compared to 2022 Achieved Record Fourth Quarter 2023 Total Revenues of $110.6 Million, an 82.0% Increase Compared to...
Catalyst Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer and Other Executive Promotions
04. Dezember 2023 08:03 ET
|
Catalyst Pharmaceuticals, Inc.
Ms. Alicia Grande, Catalyst's Current CFO, to Retire at the End of 2023 Dr. Steven Miller Promoted to Executive Vice President, Chief Operating and Scientific Officer and Jeffrey Del Carmen Promoted...
Catalyst Pharmaceuticals To Participate in Piper Sandler 35th Annual Healthcare Conference
16. November 2023 08:05 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing,...
Catalyst Pharmaceuticals Partners with Sofie's Journey to Bring Focus on Epilepsy at the 11th Annual Epilepsy Awareness and Education Expo
30. Oktober 2023 08:03 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
Catalyst Pharmaceuticals Appoints Richard J. Daly as Chief Executive Officer
19. Oktober 2023 08:03 ET
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
Ulcerative Colitis Market Soars to $6.84 Billion in 2023, Registering a 7.7% CAGR - Unlocking Lucrative Investment Opportunities
20. September 2023 04:43 ET
|
Research and Markets
Dublin, Sept. 20, 2023 (GLOBE NEWSWIRE) -- The "Ulcerative Colitis Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. The global ulcerative colitis market is...
Catalyst Pharmaceuticals Reports Positive Momentum in Second Quarter 2023
01. Juni 2023 08:03 ET
|
Catalyst Pharmaceuticals, Inc.
Reaffirms Full Year 2023 Total Revenue Guidance of Between $375 Million and $385 Million Forecasts FIRDAPSE® 2023 Net Product Revenue Guidance of Between $245 Million and $255 Million, an...
Insights on the Alopecia Treatment Global Market to 2027 - by Condition Type, Medication Type and Geography
06. Januar 2023 08:38 ET
|
Research and Markets
Dublin, Jan. 06, 2023 (GLOBE NEWSWIRE) -- The "Global Alopecia Treatment Market - Forecasts from 2022 to 2027" report has been added to ResearchAndMarkets.com's offering.The global alopecia...
Catalyst Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
16. März 2022 16:21 ET
|
Catalyst Pharmaceuticals, Inc.
Total 2021 Revenues Increased Approximately 18% YoY to $141 Million Strong 2022 Revenue Growth Expected, Supported by FIRDAPSE® Orphan Drug Exclusivity New Patent Issuances Strengthens FIRDAPSE...